SCHEMBL600153

SCHEMBL600153

NCCNCCN(CCN)CCN

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.56
CYP2C9 P11712 2/20 0.56
CA12 O43570 5/20 0.56
CA6 P23280 5/20 0.56
CA7 P43166 5/20 0.56
CA9 Q16790 5/20 0.56
CA14 Q9ULX7 5/20 0.56
CA5B Q9Y2D0 5/20 0.56
MEN1 O00255 2/20 0.56
RECQL P46063 2/20 0.56
KMT2A Q03164 2/20 0.56
CA2 P00918 4/20 0.53
CA4 P22748 4/20 0.53
CA5A P35218 4/20 0.53
TDP1 Q9NUW8 3/20 0.53
LMNA P02545 3/20 0.53
CA3 P07451 3/20 0.53
ALOX15 P16050 3/20 0.53
CA1 P00915 2/20 0.53
ALDH1A1 P00352 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9064147 1.00 CYP2C19 (0.56) CYP2C19CYP2C9CA12CA6CA7
SCHEMBL23489527 1.00 CYP2C19 (0.56) CYP2C19CYP2C9CA12CA6CA7
SCHEMBL13033247 1.00 CYP2C19 (0.56) CYP2C19CYP2C9CA12CA6CA7
SCHEMBL13330251 1.00 CYP2C19 (0.56) CYP2C19CYP2C9CA12CA6CA7
SCHEMBL23489712 0.97 CA12 (0.58) CYP2C19CYP2C9CA12CA6CA7
SCHEMBL23489642 0.97 CA12 (0.58) CYP2C19CYP2C9CA12CA6CA7
SCHEMBL23489564 0.97 CA12 (0.58) CYP2C19CYP2C9CA12CA6CA7
SCHEMBL23489526 0.97 CA12 (0.58) CYP2C19CYP2C9CA12CA6CA7
SCHEMBL23489538 0.97 CA12 (0.58) CYP2C19CYP2C9CA12CA6CA7
SCHEMBL23489816 0.97 CA12 (0.58) CYP2C19CYP2C9CA12CA6CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 496 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4695337-A1 AQUEOUS COMPOSITIONS WITH MULTI-FUNCTIONAL, NITROGENOUS, ORGANIC ADDITIVE SWIMC LLC (US) 2026-02-18 EP claimed
WO-2024215587-A1 AQUEOUS COMPOSITIONS WITH MULTI-FUNCTIONAL, NITROGENOUS, ORGANIC ADDITIVE SWIMC LLC (US) 2024-10-17 WO claimed
WO-2024115754-A1 AQUEOUS COMPOSITIONS CONTAINING POLYALKOXYLATES, POLYALKOXYLATES, AND USE BASF SE (DE) 2024-06-06 WO claimed
US-20240067858-A1 ALIPHATIC EPOXY RESIN CROSSLINKED POLYMERS FOR PRIMARY CEMENTING IN A BOREHOLE SAUDI ARABIAN OIL COMPANY (SA) 2024-02-29 US claimed
CN-115469516-B Stripping agent for III-V semiconductor compound photoresist, preparation method and application thereof 江苏奥首材料科技有限公司 2023-03-24 CN claimed
CN-115469516-A Stripping agent for photoresist of III-V semiconductor compound, preparation method and application thereof 江苏奥首材料科技有限公司 2022-12-13 CN claimed
US-20200190390-A1 ADDITIVE TO FLEXIBILIZE EPOXY-BASED RESINS FOR USE IN OIL FIELD APPLICATIONS COVESTRO LLC 2020-06-18 US claimed
WO-2019036189-A1 ADDITIVE TO FLEXIBILIZE EPOXY-BASED RESINS FOR USE IN OIL FIELD APPLICATIONS COVESTRO LLC (US) 2019-02-21 WO claimed
EP-2474528-B1 Antineoplasic compounds and pharmaceutical compositions thereof CT INGENIERIA GENETICA BIOTECH (CU) 2014-09-24 EP claimed
US-8765008-B2 Hydroxyalkylated polyalkylenepolyamine composition, method for producing same and method for producing polyurethane resin using such hydroxyalkylated polyalkylenepolyamine composition TOSOH CORPORATION (JP) 2014-07-01 US claimed
US-20120252661-A1 HYDROXYALKYLATED POLYALKYLENEPOLYAMINE COMPOSITION, METHOD FOR PRODUCING SAME AND METHOD FOR PRODUCING POLYURETHANE RESIN USING SUCH HYDROXYALKYLATED POLYALKYLENEPOLYAMINE COMPOSITION TOSOH CORPORATION (JP) 2012-10-04 US claimed
EP-2474528-A1 Antineoplasic compounds and pharmaceutical compositions thereof Centro De Ingenieria Genetica Y Biotecnologia (CU) 2012-07-11 EP claimed
US-20120041088-A1 FOAMING ADDITIVE FOR PRODUCING POLYURETHANE FOAM, AND METHOD FOR PRODUCING RIGID POLYURETHANE FOAM BY USING IT TOSOH CORPORATION (JP) 2012-02-16 US claimed
US-20080004362-A1 Hydroxyalkylated Polyalkylenepolyamine Composition, Method for Producing Same and Method for Producing Polyurethane Resin Using Such Hydroxyalkylated Polyalkylenepolyamine Composition TOSOCH CORPORATION (JP) 2008-01-03 US claimed
EP-1813599-A1 HYDROXYALKYLATED POLYALKYLENEPOLYAMINE COMPOSITION, METHOD FOR PRODUCING SAME AND METHOD FOR PRODUCING POLYURETHANE RESIN USING SUCH HYDROXYALKYLATED POLYALKYLENEPOLYAMINE COMPOSITION Tosoh Corporation (JP) 2007-08-01 EP claimed
US-20260144748-A1 POLYOL-BASED MULTI-FUNCTIONAL COMPOUNDS FOR MEDICAL APPLICATIONS AND HYDROGELS FORMED FROM SAME BOSTON SCIENTIFIC SCIMED, INC. (US) 2026-05-28 US disclosed
WO-2026104544-A1 EXO-VINYLENE CARBONATE COMPOUNDS AS PRECURSORS FOR ISOCYANATE-FREE URETHANE-TYPE POLYMERS BASF SE (DE) 2026-05-21 WO disclosed
US-4051067-A Stabilization of unsaturated carboxylic acid esters with mixtures of polyalkyleneamines and arylenediamines MONSANTO COMPANY (US) 1977-09-27 US disclosed
US-4036881-A FROM ALKYLENEAMINE AND ALKANOLAMINE TEXACO DEVELOPMENT CORPORATION (US) 1977-07-19 US disclosed
US-4016198-A Stabilization of unsaturated carboxylic acid esters with mixtures of polyalkylene-amines and arylenediamines MONSANTO COMPANY (US) 1977-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004362-A1 Hydroxyalkylated Polyalkylenepolyamine Composition, Method for Producing Same and Method for Producing Polyurethane Resin Using Such Hydroxyalkylated Polyalkylenepolyamine Composition SRM, HRH3, HNMT CYP2C19 3964/4885CYP2C9 3774/4885CA12 4484/4885
US-20260144748-A1 POLYOL-BASED MULTI-FUNCTIONAL COMPOUNDS FOR MEDICAL APPLICATIONS AND HYDROGELS FORMED FROM SAME CD44, PAM, PLOD3 CYP2C19 1961/4885CYP2C9 2499/4885CA12 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.